16 completed, 2 active not recruiting, 2 unknown, 1 recruiting. 12 Phase 2, 4 Phase 3, 3 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Active not recruiting 2, Withdrawn 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Unknown 1 |
Follow Chromosome 17 deletion: new trials by email Literature Review of Chromosome 17 deletion trials Research Report on Chromosome 17 deletion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-08-11 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Ibrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Loss of Chromosome 17p | Phase 2 | Withdrawn | Kerry Rogers | 2020-03-11 | 2021-11-05 | |
| A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients Daratumumab, Pomalidomide, Dexamethasone - Multiple Myeloma, Deletion 17P Syndrome | Phase 2 | Active not recruiting | Fondazione EMN Italy Onlus | 45 | 2019-07-01 | 2026-09-09 |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Obinutuzumab, Bendamustine, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 3 | Completed | AbbVie | 120 | 2018-08-10 | 2024-08-06 |
| Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice Chronic Lymphocytic Leukemia | Completed | AbbVie | 93 | 2018-01-10 | 2023-03-30 | |
| a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2, Melphalan Given IV - Multiple Myeloma, Plasma Cell Leukemia | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2018-01-05 | 2019-07-05 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Active not recruiting | AbbVie | 66 | 2017-10-12 | 2026-08-19 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib, Fludarabine, Pembrolizumab - B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-09-22 | 2026-01-30 |
| Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study Chronic Lymphocytic Leukemia, Del(17P) | Unknown | Fatih Demirkan, MD | 1000 | 2017-01-01 | 2021-03-09 | |
| A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Venetoclax - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | AbbVie | 210 | 2016-12-13 | 2023-02-22 |
| A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Venetoclax - Chronic Lymphocytic Leukemia | Phase 3 | Completed | AbbVie | 258 | 2016-06-22 | 2023-04-10 |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 33 | 2015-12-30 | 2024-09-19 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation Ibrutinib, Laboratory Biomarker Analysis, Nivolumab - Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-06-19 | 2024-03-20 |
| Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Acalabrutinib (Arm A), Acalabrutinib (Arm B) - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Completed | Acerta Pharma BV | 48 | 2015-01-12 | 2026-07-21 |
| A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort) - Chronic Lymphocytic Leukemia, 17p Deletion | Phase 2 | Completed | AbbVie | 158 | 2013-06-27 | 2021-12-16 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate - Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Completed | Fred Hutchinson Cancer Center | 47 | 2012-09-25 | 2020-01-02 |
| Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) POMALIDOMIDE, Dexamethasone - Multiple Myeloma | Phase 2 | Completed | University Hospital, Lille | 63 | 2012-01-01 | 2026-02-05 |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma bortezomib, fludarabine phosphate, melphalan - Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p | Phase 1 | Completed | City of Hope Medical Center | 18 | 2011-03-01 | 2026-10-22 |
| Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) CLL | Completed | European Society for Blood and Marrow Transplantation | 41 | 2010-08-01 | 2019-08-16 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Multiple Myeloma (8) · Leukemia (3) · Leukemia, B-Cell (3) · Leukemia, Plasma Cell (3) · Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Recurrence (3) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · Hematologic Neoplasms (1)
Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Immunoproliferative Disorders (23) · Neoplasms by Histologic Type (23) · Immune System Diseases (22) · Lymphoproliferative Disorders (22) · Neoplasms (20) · Leukemia, Lymphoid (18) · Lymphatic Diseases (18) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Chronic Disease (17) · Disease Attributes (17) · Leukemia (17) · Leukemia, B-Cell (14)
venetoclax (6) · fludarabine phosphate (5) · Dexamethasone (4) · Melphalan (3) · Peripheral Blood Stem Cell Transplantation (3) · ibrutinib (3) · Mycophenolic Acid (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · fludarabine (2) · pomalidomide (2) · Alemtuzumab (1) · Atorvastatin (1) · Bendamustine Hydrochloride (1) · Bortezomib (1)
AbbVie (6) · Fred Hutchinson Cancer Center (2) · Acerta Pharma BV (1) · City of Hope Medical Center (1) · European Society for Blood and Marrow Transplantation (1) · Fatih Demirkan, MD (1) · Fondazione EMN Italy Onlus (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kerry Rogers (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Memgen, LLC (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Newave Pharmaceutical Inc (1) · Rutgers, The State University of New Jersey (1)
United States (13) · France (4) · Germany (4) · Australia (3) · Canada (3) · United Kingdom (3) · Austria (2) · China (2) · Denmark (2) · Finland (2) · Israel (2) · Italy (2) · Netherlands (2) · New Zealand (2) · Poland (2)
Adrian U Wiestner, M.D. (1) · Fatih Demirkan, Prof (1) · Firoozeh Sahebi, MD (1) · Januario Castro, MD (1) · Johannes Schetelig, MD (1) · Kerry A Rogers, MD (1) · Lu G Qiu, Dr. (1) · Marco Mielcarek (1) · Mohamed Sorror (1) · Nicolaus Kroeger, MD (1) · Nitin Jain (1) · Roger Strair (1)
PMID 25575538, PMID 29063805, PMID 29715056, PMID 31023700, PMID 31467127, PMID 32054731, PMID 32202637, PMID 32499241, PMID 34632935, PMID 36287248, PMID 36442911, PMID 37227160, PMID 38290108, PMID 38467131
P30CA015704 (2), 2015 (1), 2016 (1), P01CA018029 (1), P30CA072720 (1)